37 results
SC 14D9
EX-99
KNTE
Kinnate Biopharma Inc
4 Mar 24
Tender offer solicitation
5:27pm
in your Change in Control and Severance Agreement with the Company (the “CIC Agreement”) or as set forth in Appendix A.
Transaction Bonus
If a (i … (collectively, a “Transaction”) occurs and you satisfy the Payment Condition for such Transaction, you will be entitled to receive a bonus (a “Transaction
SC 14D9
EX-99
KNTE
Kinnate Biopharma Inc
4 Mar 24
Tender offer solicitation
5:27pm
in your Change in Control and Severance Agreement with the Company (the “CIC Agreement”) or as set forth in Appendix A.
Transaction Bonus
If a (i … (collectively, a “Transaction”) occurs and you satisfy the Payment Condition for such Transaction, you will be entitled to receive a bonus (a “Transaction
SC 14D9
EX-99
KNTE
Kinnate Biopharma Inc
4 Mar 24
Tender offer solicitation
5:27pm
forth in your Change in Control and Severance Agreement with the Company (the “CIC Agreement”) or as set forth in Appendix A.
Transaction Bonus
If a (i … in Control (collectively, a “Transaction”) occurs and you satisfy the Payment Condition for such Transaction, you will be entitled to receive a bonus
SC 14D9
EX-99
KNTE
Kinnate Biopharma Inc
4 Mar 24
Tender offer solicitation
5:27pm
forth in your Change in Control and Severance Agreement with the Company (the “CIC Agreement”) or as set forth in Appendix A.
Transaction Bonus … in Control (collectively, a “Transaction”) occurs and you satisfy the Payment Condition for such Transaction, you will be entitled to receive a bonus
S-1
EX-10.8
KNTE
Kinnate Biopharma Inc
13 Nov 20
IPO registration
5:03pm
, in its sole discretion.
Annual Bonus. For each fiscal year of the Company, you will have the opportunity to earn a target annual cash bonus equal … to thirty percent (30%) (increasing to forty percent (40%) effective beginning for the Company’s fiscal 2021 bonus period) of your annual base salary earned
8-K
EX-10.1
g1rncqugsl
7 Jun 21
Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team
8:07am
S-1
EX-10.7
aey ivmsi1a
13 Nov 20
IPO registration
5:03pm
S-1
EX-10.6
gcnwxyzo nxbj
13 Nov 20
IPO registration
5:03pm
S-1
EX-10.5
i9hmzic63teeh ghju8e
13 Nov 20
IPO registration
5:03pm
S-1
EX-10.9
8pn9bm4 d66gwjbn5x2i
13 Nov 20
IPO registration
5:03pm
8-K
d6mrjg
22 Nov 23
Departure of Directors or Certain Officers
4:05pm
S-1
EX-10.11
ycf16sp u4z
13 Nov 20
IPO registration
5:03pm
S-1
EX-10.12
36h00f3o4hnuwpo3ang
13 Nov 20
IPO registration
5:03pm
S-1
EX-10.13
5ok4d8b 9ig0f99rq
13 Nov 20
IPO registration
5:03pm
8-K
EX-10.2
qd2s35i
7 Jun 21
Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team
8:07am
S-1
EX-10.10
7f7s1b5yf abjoibo9d9
13 Nov 20
IPO registration
5:03pm
8-K
9p9g uowiondf
7 Jun 21
Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team
8:07am
SC 14D9
27sqmq25nah8tktq5rd
4 Mar 24
Tender offer solicitation
5:27pm
8-K
EX-2.1
yzsdvjna7c89 2un
16 Feb 24
Entry into a Material Definitive Agreement
9:10am
DEF 14A
vkc2wi7h6id0g937ns
30 Apr 21
Definitive proxy
9:13am